RANCHO CUCAMONGA, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020 RANCHO CUCAMONGA, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020 .
RANCHO CUCAMONGA, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020 , after the market closes on Thursday, August 6th, 2020 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
RANCHO CUCAMONGA, Calif. , June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
RANCHO CUCAMONGA, Calif. , June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar ® Pharmaceuticals, Inc. , (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Succinylcholine Chloride Injection USP,
RANCHO CUCAMONGA, Calif. , June 02, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO and Dan Dischner , Vice President of Corporate Communications and Human Resources will be presenting at the Jefferies Virtual Healthcare Conference on
Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020 RANCHO CUCAMONGA, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2020 .
RANCHO CUCAMONGA, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020 , after the market closes on Thursday, May 7th, 2020 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP
